Antitope and Synthon announce collaboration

04-Jul-2014 - United Kingdom

Antitope Limited, an Abzena company, announced that it will collaborate with Synthon Biopharmaceuticals BV, to assess the potential immunogenicity of candidate antibodies for Synthon’s ADC programmes.
 
Antitope will use its EpiScreen™ technology, a highly accurate and sensitive ex vivo human T cell assay to determine the potential immunogenicity of the antibodies provided by Synthon. The EpiScreen™ technology correlates with published clinical anti-drug antibody immunogenicity data which supports selection of lead product candidates with low immunogenicity during preclinical development.

Other news from the department business & finance

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous